# Examining the Impact of Type 2 Diabetes Status and Severity on In-Hospital Outcomes Amongst Patients Hospitalized with Covid-19 in a Southwest Virginia Healthcare System



**CARILION CLINIC** 

# INTRODUCTION

- Patients with type 2 diabetes mellitus (T2DM) who develop COVID-19 are at increased risk of hospitalization, longer hospital stays, ICU admission, and death <sup>1-6</sup>
- Additionally, measures of T2DM severity (e.g., hemoglobin A1c, fasting plasma glucose) have been found to be predictive of severe COVID-19 <sup>7-8</sup>
- The present analysis was conducted to determine whether T2DM status and severity may be predictive of COVID-19 severity outcomes amongst patients hospitalized with COVID-19 in a southwest Virginia healthcare system

# MATERIALS & METHODS

## Inclusion/Exclusion Criteria

- 18 years of age or older
- Non-pregnant
- Hospitalized with COVID-19 on or before 6/11/2021
- No past diagnosis of non-T2DM diabetes mellitus

## Exposure Variables

- T2DM status (Yes/No)
- Diabetes Complications Severity Index (DCSI) score
  - 13-point summary score covering 7 discrete categories of diabetes complications 9-10

## Outcome Variables

- Progression to ICU admission, ventilatory assistance, and/or death (Yes/No)
- In-hospital mortality (Yes/No)

## Statistical Methods

- Binary logistic regression was used to assess the relationship between T2DM status and COVID-19 severity
- Multivariate logistic regression was used to assess the relationship between DCSI score and COVID-19 severity amongst diabetics
- Propensity score weighting was used to adjust for covariates including age, sex, race/ethnicity, BMI, and smoking status; covariates were selected according to the directed acyclic graph included in Figure 1



## Figure 1: Hypothesized Causal Mechanism



Causal link

Exposure/Outcome Potential confounder;

Controlled for analytically Potential confounder; Controlled for via exclusion

Not a potential confounder

## Jesse Bendetson, MPH<sup>1</sup>, Anthony Baffoe-Bonnie, MD<sup>1,2</sup> <sup>1</sup>Virginia Tech Carilion School of Medicine (VTCSOM); <sup>2</sup>Carilion Clinic

RESULTS



Hospitalized; No ICU/Ventilator (n = 761) ICU/Ventilator; No Death (n = 201)

65.8%

■ Death (n = 195)

17.4%



	Diabetics (n = 942)	Non-Diabetics (n = 1,157)			
n	%	n	%		
444	47.1%	626	54.1%		
498	52.9%	531	45.9%		
136	14.4%	126	10.9%		
760	80.7%	951	82.2%		
29	3.1%	53	4.6%		
17	1.8%	27	2.3%		
10	1.1%	72	6.2%		
26	2.8%	78	6.7%		
61	6.5%	112	9.7%		
159	16.9%	178	15.4%		
248	26.3%	223	19.3%		
275	29.2%	261	22.6%		
163	17.3%	233	20.1%		
318	33.8%	382	33.0%		
624	66.2%	775	67.0%		
8	0.9%	43	3.7%		
143	15.2%	259	22.4%		
248	26.3%	323	27.9%		
207	22.0%	225	19.5%		
336	35.7%	207	26.5%		







## Table 2: Logistic Regre

**COVID-19 Severity Ind** Progression to ICU adr ventilatory assistance In-hospital mortality

## Table 3: Logistic Reg

DC3I Score	
0	
1	
2	
3	
4	

5+

Note: All logistic regression analyses utilized propensity score weighting to adjust for covariates including age, sex, race/ethnicity, BMI, and smoking status.

- COVID-19 severity outcomes

## **REFERENCES & ACKNOWLEDGEMENTS**

The researchers would like to acknowledge all of the participants who contributed their data to this research.

10.1186/s13054-020-02902-w, PMID: 32345311; PMCID: PMC7187660 10.1001/jama.2020.2648. PMID: 32091533. PMC7426088. 2020 Jul 10. PMID: 32647915; PMCID: PMC7347402. Care. 2008 Jan;14(1):15-23. PMID: 18197741; PMCID: PMC3810070.

10.Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6. PMID: 23198714.

# **Virginia Tech Carilion** School of Medicine

# **RESULTS (CONT.)**

Figure 5: COVID-19 Severity Amongst Diabetics by DCSI Score (n = 942)

				1		1					
		70.9%					25.6%		3.5%		
	6	6.2%					22.1%	/ 0	11.8%		
	59.	5%				21.0%		19.5%			
Z	46.3%			19.8%			34.0%				
41	.7%		2	20.0% 38.3%							
42	.2%			23.8%			3	84.0%			
No ICU/Ventilator ICU/Ventilator; No Death Death											
ession – Diabetes Status and COVID-19 Severity (n = 2,099)											
n <b>dica</b> mise	a <b>tor</b> sion, l/or death	<b>Odds I</b> 1.51	Ratio		<b>95%</b> 1.16	<b>ώ Cc</b> δ, 1.	onfidence 96	Interval			
Gire		1.39		1.02	1.02, 1.91						
gression – DCSI Status and In-Hospital COVID-19 Mortality Amongst Diabetics (n = 942)											
		Odds Ratio				95% Confidence Interval					
				<b></b>							
	3.229				1.199, 8.697						
4.910				1.949, 12.372							
		9.824	6			3.929, 24.560 4.329, 38.338					
		11.076									
		11,251	.251			4.457.28.397					

## CONCLUSION

Amongst this sample of patients hospitalized with COVID-19, diabetes status was associated with in-hospital COVID-19 severity outcomes including ICU admission, need for ventilatory support, and mortality

Amongst individuals with T2DM, DCSI score was found to predict in-hospital

A major limitation of this study is that we have not yet been able to parse out how changes in vaccine coverage and strain dominance over time may have affected these relationships; future work will attempt to address these issues

1.Li Y, Ashcroft T, Chung A, et al. Risk factors for poor outcomes in hospitalised COVID-19 patients: A systematic review and meta-analysis. J Glob Health. 2021 Mar 1;11:10001. doi: 10.7189/jogh.11.10001. PMID: 33767855; PMCID: PMC7980087.

2.Nguyen TH, Shah GH, Schwind JS, Richmond HL. Community Characteristics and COVID-19 Outcomes: A Study of 159 Counties in Georgia, United States. J Public Health Manag Pract. 2021 May-Jun 01;27(3):251-257. doi: 10.1097/PHH.00000000000001330. PMID: 33762540. 3.Cheng S, Zhao Y, Wang F, Chen Y, Kaminga AC, Xu H. Comorbidities' potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis. Medicine (Baltimore). 2021 Mar 26;100(12):e24971. doi: 10.1097/MD.0000000000024971. PMID: 33761654.

4.Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020 Apr 28;24(1):179. doi: 5.Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a

Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi:

6.Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822. doi: 10.1016/S2213-8587(20)30272-2. Epub 2020 Aug 13. PMID: 32798472; PMCID:

7.Merzon E, Green I, Shpigelman M, et al. Haemoglobin A1c is a predictor of COVID-19 severity in patients with diabetes. Diabetes Metab Res Rev. 2020 Aug 27:e3398. doi: 10.1002/dmrr.3398. Epub ahead of print. PMID: 32852883; PMCID: PMC7460936. 8.Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020 Oct;63(10):2102-2111. doi: 10.1007/s00125-020-05209-1. Epub

9.Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag

